Nanjing Xinjiekou Department Store Co Ltd

Nanjing Xinjiekou Department Store disclosed its 2026 semi-annual report on the evening of August 26, reporting first-half operating revenue of 2.89 billion yuan and total profit of 163 million yuan. The company adhered to its dual-engine strategy of "big health plus new consumption," with progress across its modern commerce, health and elderly care, and biomedical segments. In modern commerce, the company advanced store renovations, introduced first stores and benchmark brands, and created younger-oriented consumption scenarios. In health and elderly care, Ankangtong won 82 projects, while overseas subsidiary Natali completed the acquisition and integration of several UK elderly care companies. In biomedicine, Qilu Stem Cell completed filings for two new technologies, and Dendreon China's Provenge is in Phase III clinical follow-up. The company said it will continue to seize opportunities in the silver economy and the cell and gene therapy industry to promote high-quality development.